Pharma Equity Group Board Decides To Issue Convertible Loans
Pharma Equity Group A/S Class A
No trades
No trades
Headlines
Pharma Equity Group A/S (PEG) Approves Convertible Loans Up to DKK 4.13M
The Board of Directors' resolution on the issuance of convertible loans
PEG: Interpatium Commences Proceedings To Set Aside Arbitral Award
Pharma Equity Group A/S – Challenge to Arbitral Award
PEG: Net loss improved to DKK -2.7m, with strengthened IP and ongoing licensing discussions
PEG: Net loss narrowed as clinical progress and a key legal win improved financial position, but funding needs persist
Correction to Consolidated Interim Report 1 January – 30 June 2026
Pharma Equity Maintains Financial Guidance For 2026
Pharma Equity Group consolidated Interim Report 1 January – 30 June 2026
Pharma Equity Group prevails in international arbitration proceedings and is awarded EUR 10.5 million excluding interest and costs
Pharma Equity Group Unit Gets Patent Grant Notification
Pharma Equity Group’s subsidiary Reponex takes key step forward in Inflammatory Bowel Disease with upcoming European patent grant
Pharma Equity Group To Borrow Up To About DKK 9.63 Million
Proceedings of the Annual General Meeting of Pharma Equity Group A/S
Notice convening the annual general meeting in Pharma Equity Group A/S
PEG: Loss narrowed, clinical milestones advanced, and 2026 guidance targets first revenue
PEG: Loss before tax narrowed to DKK -26.4 million amid clinical progress and ongoing funding efforts
Pharma Equity Group A/S - Annual Report 2025
UPDATE OF THE FINANCIAL CALENDAR FOR 2026